# US 2025/0367191 A1 · Treatment of mitochondrial diseases with a cns-penetrant sgc stimulator zagociguat

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0367191 A1
- Document ID: US20250367191A1
- Status: Published application
- Kind: A1
- Application number: 18/872,750
- Filed: 2023-06-09
- Published: 2025-12-04
- Earliest claimed: 2022-06-09
- Assignees: Tisento Therapeutics Inc.
- Applicants: Tisento Therapeutics Inc.
- Inventors: Chad Edward Glasser; Christopher John Winrow
- Web page: https://patentgrep.com/patent/US20250367191A1

## CPC

- A61K 31/4985: Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a method of treating a mitochondrial disease in a patient in need thereof by administering Compound (I), a stimulator of soluble guanylate cyclase (sGC) at certain dosages either alone or in combination therapy.

## Claims

### Claim 1

A method of treating mitochondrial disease in a patient in need thereof comprising administering to said patient a total oral daily dose of between 15 mg and 60 mg of Compound I:

### Claim 2 (depends on 1)

The method of claim 1, wherein the mitochondrial disease is selected from Alpers Disease, Autosomal Dominant Optic Atrophy (ADOA), Barth Syndrome/LIC (Lethal Infantile Cardiomyopathy), Beta-oxidation defects, Long Chain Fatty Acid Transport Deficiency, Co-Enzyme Q10 Deficiency, Complex I, II, III, IV, V Deficiency, Chronic Progressive External Ophthalmoplegia (CPEO), Friedreich's Ataxia, Kearns-Sayre syndrome, Leukodystrophy, Leigh Disease or Syndrome, LHON, LHON Plus, MELAS (Mitochondrial myopathy, encephalomyopathy, lactic acidosis, stroke-like symptoms), Myoclonic Epilepsy with Ragged Red Fibers (MERRF), Mitochondrial Recessive Ataxia Syndrome (MIRAS), Mitochondrial Cytopathy, Mitochondrial DNA Depletion, Mitochondrial Encephalopathy, Mitochondrial Myopathy, Multiple Mitochondrial Dysfunction Syndrome, MNGIE (Myoneurogenic gastrointestinal encephalopathy), NARP (Neuropathy, ataxia, retinitis pigmentosa, and ptosis), Pearson Syndrome, Pyruvate Carboxylase Deficiency, Pyruvate Dehydrogenase Deficiency or Pyruvate Dehydrogenase Complex Deficiency (PDCD/PDH), and POLG Mutations.

### Claim 3 (depends on 1)

The method of claim 1, wherein the mitochondrial disease is selected from Alpers, Complex I, II, III, IV deficiency, CPEO, KSS, LCHAD, Leigh syndrome, Leukodystrophy, LHON, MELAS, MEPAN, MERRF, MIRAS, Mitochondrial DNA depletion, MNGIE, NARP, Pearson syndrome, and POLG mutations.

### Claim 4 (depends on 1)

The method of claim 1, wherein the mitochondrial disease is a Complex I mitochondrial disease.

### Claim 5 (depends on 1)

The method of claim 1, wherein the mitochondrial disease is MELAS.

### Claim 6 (depends on 1)

The method of claim 1, wherein the mitochondrial disease is Leigh syndrome.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The method of any one of claims 1-6, wherein the patient is 16 years or older, 18 years or older or 65 years or older.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6)

The method of any one of claims 1-6, wherein the patient is between 16 and 75, between 16 and 70, between 16 and 65, between 16 and 60, between 16 and 55, between 16 and 50, between 16 and 40, or between 16 and 30 years old.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6)

The method of any one of claims 1-6, wherein the patient is younger than 65 years old, younger than 60 years old, younger than 50 years old, younger than 40 years old, younger than 30 years old or younger than 20 years old.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6)

The method of any one of claims 1-6, wherein the patient is 16 years old or younger, 12 years old or younger, 10 years old or younger, or 5 years old or younger.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6)

The method of any one of claims 1-6, wherein the patient is between 3 and 18, between 3 and 12, between 5 and 18, between 5 and 12, or between 3 and 5 years old.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The method of any one of claims 1 to 11, wherein the patient is administered a total oral daily dose of 15 mg of Compound I.

### Claim 13 (depends on 12)

The method of claim 12, wherein the patient is administered a single oral daily dose of 15 mg of Compound I.

### Claim 14 (depends on 12)

The method of claim 12, wherein the patient is administered two oral daily doses of 7.5 mg of Compound I.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The method of any one of claims 1 to 11, wherein the patient is administered a total oral daily dose of 20 mg of Compound I.

### Claim 16 (depends on 15)

The method of claim 15, wherein the patient is administered a single oral daily dose of 20 mg of Compound I.

### Claim 17 (depends on 15)

The method of claim 15, wherein the patient is administered two oral daily doses of 10 mg of Compound I.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The method of any one of claims 1 to 11, wherein the patient is administered a total oral daily dose of 25 mg of Compound I.

### Claim 19 (depends on 18)

The method of claim 18, wherein the patient is administered a single oral daily dose of 25 mg of Compound I.

### Claim 20 (depends on 18)

The method of claim 18, wherein the patient is administered two oral daily dose of 12.5 mg of Compound I.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The method of any one of claims 1 to 11, wherein the patient is administered a total oral daily dose of 30 mg of Compound I.

### Claim 22 (depends on 21)

The method of claim 21, wherein the patient is administered a single oral daily dose of 30 mg of Compound I.

### Claim 23 (depends on 21)

The method of claim 21, wherein the patient is administered two oral daily dose of 15 mg of Compound I.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The method of any one of claims 1 to 11, wherein the patient is administered a total oral daily dose of 45 mg of Compound I.

### Claim 25 (depends on 24)

The method of claim 24, wherein the patient is administered a single oral daily dose of 45 mg of Compound I.

### Claim 26 (depends on 24)

The method of claim 24, wherein the patient is administered two oral daily dose of 22.5 mg of Compound I.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The method of any one of claims 1 to 11, wherein the patient is administered a total oral daily dose of 60 mg of Compound I.

### Claim 28 (depends on 27)

The method of claim 27, wherein the patient is administered a single oral daily dose of 60 mg of Compound I.

### Claim 29 (depends on 24)

The method of claim 24, wherein the patient is administered two oral daily dose of 30 mg of Compound I.

### Claim 30 (depends on 14, 17, 20, 23, 26, 29)

The method of claim 14, 17, 20, 23, 26 or 29, wherein the patient is administered a first dose and a second dose, wherein the first dose and the second dose are separated by a period between 5 hours and 15 hours, between 8 hours and 15 hours, or between 10 hour and 15 hours.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

The method of any one of claims 1 to 30, wherein treatment with Compound I results in a measurable improvement in neuronal function and connectivity.

### Claim 32 (depends on 31)

The method of claim 31, wherein the improvement in neuronal function and connectivity is measured by functional magenic resonance imaging (fMRI).

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

The method of any one of claims 1 to 32, wherein treatment with Compound I results in an increase in cerebral blood flow (CBF).

### Claim 34 (depends on 33)

The method of claim 33, wherein the treatment with Compound I results in an increase in cerebral blood flow (CBF) in a brain region selected from temporal lobe, parietal lobe, occipital lobe, frontal lobe, corpus callosum, cingulate lobe, cerebral white matter and cerebellar white matter, or a combination of one or more aforementioned regions.

### Claim 35 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)

The method of any one of claims 1 to 34, wherein treatment with Compound I results in a reduction in one or more biomarkers of mitochondrial dysfunction.

### Claim 36 (depends on 35)

The method of claim 35, wherein the one or more biomarkers of mitochondrial dysfunction are selected from lactate, GDF-15 and FGF-21.

### Claim 37 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)

The method of any one of claims 1 to 36, wherein treatment with Compound I results in a reduction in one or more inflammatory biomarkers.

### Claim 38 (depends on 37)

The method of claim 37, wherein the one or more inflammatory biomarkers are selected from VCAM-1, ICAM, vWF, and TNFR2.

### Claim 39 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

The method of any one of claims 1 to 38, further comprising administering to the patient one or more additional therapeutic agent.

### Claim 40 (depends on 39)

The method of claim 39, wherein the additional therapeutic agent is selected from citrulline and arginine.

### Claim 41 (depends on 39)

The method of claim 39, wherein the additional therapeutic agent is a mito cocktail.

### Claim 42 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41)

The method of any one of claims 1 to 41, wherein the patient has been treated with one or more other therapeutic agent used for treating mitochondrial disease.

### Claim 43 (depends on 42)

The method of claim 42, wherein the other therapeutic agent used for treating mitochondrial disease is selected from citrulline and arginine.

### Claim 44 (depends on 42)

The method of claim 42, wherein the other therapeutic agent is a mito cocktail.
